DE69727241D1 - Gesteigerte stimulation der erythropoesis - Google Patents

Gesteigerte stimulation der erythropoesis

Info

Publication number
DE69727241D1
DE69727241D1 DE69727241T DE69727241T DE69727241D1 DE 69727241 D1 DE69727241 D1 DE 69727241D1 DE 69727241 T DE69727241 T DE 69727241T DE 69727241 T DE69727241 T DE 69727241T DE 69727241 D1 DE69727241 D1 DE 69727241D1
Authority
DE
Germany
Prior art keywords
epo
hemoglobin
heme
containing components
erythropoiesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69727241T
Other languages
English (en)
Inventor
David Bell
G Mueller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hemosol Inc
Original Assignee
Hemosol Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hemosol Inc filed Critical Hemosol Inc
Application granted granted Critical
Publication of DE69727241D1 publication Critical patent/DE69727241D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/14—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69727241T 1996-08-27 1997-08-27 Gesteigerte stimulation der erythropoesis Expired - Lifetime DE69727241D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2463296P 1996-08-27 1996-08-27
PCT/CA1997/000601 WO1998008537A1 (en) 1996-08-27 1997-08-27 Enhanced stimulation of erythropoiesis

Publications (1)

Publication Number Publication Date
DE69727241D1 true DE69727241D1 (de) 2004-02-19

Family

ID=21821593

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69727241T Expired - Lifetime DE69727241D1 (de) 1996-08-27 1997-08-27 Gesteigerte stimulation der erythropoesis

Country Status (8)

Country Link
US (1) US20020120098A1 (de)
EP (1) EP0939644B1 (de)
JP (1) JP2002515880A (de)
AT (1) ATE257712T1 (de)
AU (1) AU733714B2 (de)
CA (1) CA2263978A1 (de)
DE (1) DE69727241D1 (de)
WO (1) WO1998008537A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0885613A1 (de) 1997-06-21 1998-12-23 Roche Diagnostics GmbH Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin
AU769538B2 (en) 1998-04-24 2004-01-29 Hemosol Inc. Efficient ex vivo expansion of CD4+ and CD8+ T-cells from HIV infected subjects
WO1999067360A2 (en) * 1998-06-25 1999-12-29 Hemosol Inc. Media and methods for expansion of erythroid stem cells for the production of hemoglobin
US20030162833A1 (en) 2001-08-01 2003-08-28 Roe Charles R. Fatty acid treatment for cardiac patients
IL144645A0 (en) * 1999-02-05 2002-05-23 Baylor University Medical Ct Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid
DE10002803A1 (de) * 2000-01-24 2001-08-02 Conbio Lizenzverwertungsgesell System zur internen qualitativen und quantitativen Validierung von Markerindices
US7354730B2 (en) 2002-01-29 2008-04-08 Hemogenix, Inc. High-throughput assay of hematopoietic stem and progenitor cell proliferation
US7666615B2 (en) 2001-01-29 2010-02-23 Hemogenix, Inc. High-throughput assay of hematopoietic stem and progenitor cell proliferation
AU2002335610C1 (en) 2001-01-29 2008-09-25 Hemogenix, Inc. High-throughput stem cell assay of hematopoietic stem and progenitor cell proliferation
US7989178B2 (en) 2001-01-29 2011-08-02 Hemogenix, Inc. Colony assay miniaturization with enumeration output
DE10215315A1 (de) * 2002-04-05 2003-11-20 Aventis Behring Gmbh Intellect Human-Transferrin zur Behandlung der Anaemia of Chronic Disease (ACD) und des funktionellen Eisenmangels
DE102004063927A1 (de) * 2004-01-23 2005-12-15 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
JP2007217283A (ja) * 2004-03-30 2007-08-30 Niigata Tlo:Kk 血管新生促進剤および血管新生療法
BRPI0418742A (pt) * 2004-04-14 2007-09-11 Celgene Corp métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
US7759306B2 (en) 2006-05-16 2010-07-20 Simoni Jan S Methods of treating acute blood loss
WO2009137836A2 (en) * 2008-05-09 2009-11-12 Hemogenix, Inc. Cell potency assay
KR101958612B1 (ko) 2011-09-23 2019-03-14 블루버드 바이오, 인코포레이티드. 개선된 유전자 치료 방법
WO2014113593A1 (en) * 2013-01-18 2014-07-24 Advanced Diagnostic Technologies, Llc Methods and compositions for preparing blood substitutes
CN110548133A (zh) * 2019-08-30 2019-12-10 西北大学 血红蛋白及血红蛋白衍生物在制备用于提高免疫功能的注射药物制剂方面的用途
CN110531090A (zh) * 2019-08-30 2019-12-03 西北大学 血红蛋白及血红蛋白衍生物在制备用于抗贫血的注射药物制剂方面的用途
CN114317436A (zh) * 2021-12-30 2022-04-12 中国人民解放军军事科学院军事医学研究院 一种重新激活人γ-珠蛋白基因表达的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0441119A3 (en) * 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
AU645131B2 (en) * 1990-07-31 1994-01-06 Rockefeller University, The Use of metalloporphyrins to potentiate aids therapy
CA2123094C (en) * 1991-11-06 1999-08-10 Paulo N. Correa Cell culture medium
WO1994021682A1 (en) * 1993-03-16 1994-09-29 Hemosol Inc. Selective crosslinking of hemoglobins by oxidized, ring-opened saccharides
US5545328A (en) * 1993-09-21 1996-08-13 Hemosol Inc. Purification of hemoglobin by displacement chromatography
CA2106612C (en) * 1993-09-21 2001-02-06 Diana Pliura Displacement chromatography process
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
US5861483A (en) * 1996-04-03 1999-01-19 Pro-Neuron, Inc. Inhibitor of stem cell proliferation and uses thereof
US6537777B1 (en) * 1998-07-27 2003-03-25 Hemebiotech A/S Human porphobilinogen deaminase sequences

Also Published As

Publication number Publication date
WO1998008537A1 (en) 1998-03-05
JP2002515880A (ja) 2002-05-28
ATE257712T1 (de) 2004-01-15
US20020120098A1 (en) 2002-08-29
EP0939644A1 (de) 1999-09-08
AU733714B2 (en) 2001-05-24
CA2263978A1 (en) 1998-03-05
AU4006597A (en) 1998-03-19
EP0939644B1 (de) 2004-01-14

Similar Documents

Publication Publication Date Title
ATE257712T1 (de) Gesteigerte stimulation der erythropoesis
BR9913319A (pt) Composições e métodos para tratamento de doenças mitocondriais
IL138723A0 (en) Antitumor agent
DE69914726D1 (de) Zusammensetzung zur regulierung des hauterscheinungsbildes
NZ326874A (en) 6-phenylpyridyl-2-amine derivatives
AU2118488A (en) Improvements in or relating to methods of treating damaged skin
AU6414994A (en) Composition and method for reducing toxicity of biologically-active factors
ATE121939T1 (de) Ascorbinsäure-tocopheryl-phosphatdiester zur hemmung der maillard-reaktion.
MY121294A (en) Novel hexanoic acid derivatives.
IL104006A0 (en) Azaheterocyclylmethyl-chromans,their preparation and pharmaceutical compositions containing them
WO2002038171A3 (en) METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF α-L-IDURONIDASE
AU6567086A (en) Compositions and methods for the treatment of bleeding disorders
CA2388939A1 (en) Therapeutic treatments for blood cell deficiencies
EP0506658A4 (en) Compositions and method for treating painful, inflammatory or allergic disorders
AU2246292A (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
AU6178198A (en) Method of treating a tumor
BR9500436A (pt) Produtos uso de um g-csf uso de uma proteína tnf ligante processo para o tratamento e/ou prevenção do choque séptico
ES2106531T3 (es) Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso.
GR3026086T3 (en) L-carnitine salt and cosmetic and pharmaceutical compositions containing same for treating dermatoses
AU587054B2 (en) Novel pharmaceutical compositions intended to the treatment of neuropathies and insuring the nervous regeneration
IE861148L (en) Compound for treating bone disorders
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
CA2108330A1 (en) Enhancer for the Antianemia Effect of Erythropoietin and Method of Augmenting the Antianemia Effect of Erythropoietin
HUT52377A (en) Process for producing pharmaceutical compositions comprising 3-substituted-2-oxindole-1-carboxamide derivatives as active ingredient
WO2002005801A3 (en) Compositions containing diacyltartaric salts of (e)-metanicotine

Legal Events

Date Code Title Description
8332 No legal effect for de